Five different psychiatric illnesses share a handful of genetic risk factors, report researchers in The Lancet.
Four DNA mutations were discovered in the genomes of people who had at least one of five distinct disorders: attention deficit-hyperactivity disorder, autism, bipolar disorder, major depressive disorder and schizophrenia. The findings feed into a broader goal of “moving beyond descriptive syndromes in psychiatry and towards a [classification] informed by disease cause,” write the researchers in their report.
Two of the genetic variants are not linked to any particular gene function, but the other two are found in genes involved in controlling the flow of calcium in neurons, which regulates the brain cells’ activity. There’s a chance, then, that one kind of drug could treat multiple disorders. As lead study author Jordan Smoller of Harvard Medical School and Massachusetts General Hospital told the New York Times:
“The calcium channel findings suggest that perhaps—and this is a big if —treatments to affect calcium channel functioning might have effects across a range of disorders,”
The team examined the genomes of 33,332 patients with at least one of the disorders and compared them to the genomes of 27,888 people without, making the project the largest ever genetic study of psychiatric illness, say the researchers.
Their results suggest that same mutation may lead to different disorders in different people, depending on other factors. As Judith Rapoport, chief of the child psychiatry branch at the National Institute of Mental Health, told the Boston Globe:
“There’s a sense in psychiatry there may be some very common genetic variants that, let’s say hypothetically, very early on affect very early brain development. . . . Then, maybe environment, or interactions with other genes” causes a particular illness to develop.
The results point to a future were quantitative genetic data could be incorporated into qualitative clinical diagnoses. In an accompanying commentary, psychiatrist researchers Alessandro Serretti and Chiara Fabbri from the University of Bologna in Italy write “the present study might contribute to future [classification] systems, which could be based not only on statistically determined clinical categories, but also on biological pathogenic factors that are pivotal to the identification of suitable treatments.”
The big new idea for making self-driving cars that can go anywhere
The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.
Inside Charm Industrial’s big bet on corn stalks for carbon removal
The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.
The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.